BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 19713456)

  • 1. Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors.
    Koreth J; Stevenson KE; Kim HT; Garcia M; Ho VT; Armand P; Cutler C; Ritz J; Antin JH; Soiffer RJ; Alyea EP
    Blood; 2009 Oct; 114(18):3956-9. PubMed ID: 19713456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation.
    Koreth J; Stevenson KE; Kim HT; McDonough SM; Bindra B; Armand P; Ho VT; Cutler C; Blazar BR; Antin JH; Soiffer RJ; Ritz J; Alyea EP
    J Clin Oncol; 2012 Sep; 30(26):3202-8. PubMed ID: 22869883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial.
    Koreth J; Kim HT; Lange PB; Bindra B; Reynolds CG; Chammas MJ; Armand P; Cutler CS; Ho VT; Glotzbecker B; Nikiforow S; Ritz J; Blazar BR; Soiffer RJ; Antin JH; Alyea EP
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1907-13. PubMed ID: 26055298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.
    Ho VT; Aldridge J; Kim HT; Cutler C; Koreth J; Armand P; Antin JH; Soiffer RJ; Alyea EP
    Biol Blood Marrow Transplant; 2009 Jul; 15(7):844-50. PubMed ID: 19539216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serologically HLA-DR-mismatched unrelated donors might provide a valuable alternative in allogeneic transplantation: experience from a single japanese institution.
    Inamoto Y; Kuwatsuka Y; Oba T; Terakura S; Sugimoto K; Tsujimura A; Takahashi T; Yasuda T; Miyamura K; Kodera Y
    Int J Hematol; 2007 Feb; 85(2):163-9. PubMed ID: 17321996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bortezomib-based immunosuppression after reduced-intensity conditioning hematopoietic stem cell transplantation: randomized phase II results.
    Koreth J; Kim HT; Lange PB; Poryanda SJ; Reynolds CG; Rai SC; Armand P; Cutler CS; Ho VT; Glotzbecker B; Yusuf R; Nikiforow S; Chen YB; Dey B; McMasters M; Ritz J; Blazar BR; Soiffer RJ; Antin JH; Alyea EP
    Haematologica; 2018 Mar; 103(3):522-530. PubMed ID: 29326124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma.
    Chen YB; Li S; Fisher DC; Driscoll J; Del Rio C; Abramson J; Armand P; Barnes J; Brown J; Cutler C; El-Jawahri A; Ho VT; Hochberg E; McAfee S; Takvorian R; Spitzer TR; Antin JH; Soiffer R; Jacobsen E
    Biol Blood Marrow Transplant; 2015 Sep; 21(9):1583-8. PubMed ID: 26009261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors.
    Carnevale-Schianca F; Caravelli D; Gallo S; Coha V; D'Ambrosio L; Vassallo E; Fizzotti M; Nesi F; Gioeni L; Berger M; Polo A; Gammaitoni L; Becco P; Giraudo L; Mangioni M; Sangiolo D; Grignani G; Rota-Scalabrini D; Sottile A; Fagioli F; Aglietta M
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):459-466. PubMed ID: 28039079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.
    Alyea EP; Li S; Kim HT; Cutler C; Ho V; Soiffer RJ; Antin JH
    Biol Blood Marrow Transplant; 2008 Aug; 14(8):920-6. PubMed ID: 18640576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis.
    Bolaños-Meade J; Hamadani M; Wu J; Al Malki MM; Martens MJ; Runaas L; Elmariah H; Rezvani AR; Gooptu M; Larkin KT; Shaffer BC; El Jurdi N; Loren AW; Solh M; Hall AC; Alousi AM; Jamy OH; Perales MA; Yao JM; Applegate K; Bhatt AS; Kean LS; Efebera YA; Reshef R; Clark W; DiFronzo NL; Leifer E; Horowitz MM; Jones RJ; Holtan SG;
    N Engl J Med; 2023 Jun; 388(25):2338-2348. PubMed ID: 37342922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203).
    Bolaños-Meade J; Reshef R; Fraser R; Fei M; Abhyankar S; Al-Kadhimi Z; Alousi AM; Antin JH; Arai S; Bickett K; Chen YB; Damon LE; Efebera YA; Geller NL; Giralt SA; Hari P; Holtan SG; Horowitz MM; Jacobsohn DA; Jones RJ; Liesveld JL; Logan BR; MacMillan ML; Mielcarek M; Noel P; Pidala J; Porter DL; Pusic I; Sobecks R; Solomon SR; Weisdorf DJ; Wu J; Pasquini MC; Koreth J
    Lancet Haematol; 2019 Mar; 6(3):e132-e143. PubMed ID: 30824040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial.
    Walker I; Panzarella T; Couban S; Couture F; Devins G; Elemary M; Gallagher G; Kerr H; Kuruvilla J; Lee SJ; Moore J; Nevill T; Popradi G; Roy J; Schultz KR; Szwajcer D; Toze C; Foley R;
    Lancet Haematol; 2020 Feb; 7(2):e100-e111. PubMed ID: 31958417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short Course of Post-Transplantation Cyclophosphamide and Bortezomib for Graft-versus-Host Disease Prevention after Allogeneic Peripheral Blood Stem Cell Transplantation Is Feasible and Yields Favorable Results: A Phase I Study.
    Al-Homsi AS; Cole K; Bogema M; Duffner U; Williams S; Mageed A
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1315-20. PubMed ID: 25765556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The combination of sirolimus plus tacrolimus improves outcome after reduced-intensity conditioning, unrelated donor hematopoietic stem cell transplantation compared with cyclosporine plus mycofenolate.
    Perez-Simón JA; Martino R; Parody R; Cabrero M; Lopez-Corral L; Valcarcel D; Martinez C; Solano C; Vazquez L; Márquez-Malaver FJ; Sierra J; Caballero D
    Haematologica; 2013 Apr; 98(4):526-32. PubMed ID: 23065527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of graft-versus-host disease prophylaxis including bortezomib for allogeneic hematopoietic cell transplantation from unrelated donors with one or two HLA loci mismatches in Japanese patients.
    Nakane T; Okamura H; Tagaito Y; Koh S; Yoshimura T; Makuuchi Y; Nanno S; Nakamae M; Hirose A; Nakashima Y; Koh H; Hino M; Nakamae H
    Int J Hematol; 2019 Dec; 110(6):736-742. PubMed ID: 31560116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy.
    Shore T; Harpel J; Schuster MW; Roboz GJ; Leonard JP; Coleman M; Feldman EJ; Silver RT
    Biol Blood Marrow Transplant; 2006 Aug; 12(8):868-75. PubMed ID: 16864057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic Transplantation after Myeloablative Rituximab/BEAM ± Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results.
    Chamoun K; Milton DR; Ledesma C; Young KH; Jabbour EJ; Alatrash G; Anderlini P; Bashir Q; Ciurea SO; Marin D; Molldrem JJ; Olson AL; Oran B; Popat UR; Rondon G; Champlin RE; Gulbis AM; Khouri IF
    Biol Blood Marrow Transplant; 2019 Jul; 25(7):1347-1354. PubMed ID: 30826465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation.
    Gaballa S; Ge I; El Fakih R; Brammer JE; Kongtim P; Tomuleasa C; Wang SA; Lee D; Petropoulos D; Cao K; Rondon G; Chen J; Hammerstrom A; Lombardi L; Alatrash G; Korbling M; Oran B; Kebriaei P; Ahmed S; Shah N; Rezvani K; Marin D; Bashir Q; Alousi A; Nieto Y; Qazilbash M; Hosing C; Popat U; Shpall EJ; Khouri I; Champlin RE; Ciurea SO
    Cancer; 2016 Nov; 122(21):3316-3326. PubMed ID: 27404668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation.
    Ratanatharathorn V; Nash RA; Przepiorka D; Devine SM; Klein JL; Weisdorf D; Fay JW; Nademanee A; Antin JH; Christiansen NP; van der Jagt R; Herzig RH; Litzow MR; Wolff SN; Longo WL; Petersen FB; Karanes C; Avalos B; Storb R; Buell DN; Maher RM; Fitzsimmons WE; Wingard JR
    Blood; 1998 Oct; 92(7):2303-14. PubMed ID: 9746768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation.
    Cutler C; Li S; Ho VT; Koreth J; Alyea E; Soiffer RJ; Antin JH
    Blood; 2007 Apr; 109(7):3108-14. PubMed ID: 17138818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.